Novel insights into atopic dermatitis

Recent research into the pathophysiology and treatment of atopic dermatitis (AD) has shown notable progress. An increasing number of aspects of the immune system are being implicated in AD, including the epithelial barrier, TH2 cytokines, and mast cells. Major advances in therapeutics were made in b...

Full description

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 151; no. 5; pp. 1145 - 1154
Main Authors Schuler, Charles F., Billi, Allison C., Maverakis, Emanual, Tsoi, Lam C., Gudjonsson, Johann E.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.05.2023
Subjects
Atopic dermatitis
Biomarkers
Cytokines
Dermatitis, Atopic - diagnosis
Dermatitis, Atopic - epidemiology
Dermatitis, Atopic - therapy
epithelial barrier
Humans
Immune System
Janus kinase inhibitors
Mast Cells
TH2
ILC
AD
GWAS
OR
TRPV
TRPV3
TRPV1
MR1
COVID-19
EASI
TRP
epithelial barrier
Atopic dermatitis
Janus kinase inhibitors
JAK
JAKi
TH2
T(H)2
Online AccessGet full text

Cover

More Information
Summary:Recent research into the pathophysiology and treatment of atopic dermatitis (AD) has shown notable progress. An increasing number of aspects of the immune system are being implicated in AD, including the epithelial barrier, TH2 cytokines, and mast cells. Major advances in therapeutics were made in biologic cytokine and receptor antagonists and among Janus kinase inhibitors. We focus on these areas and address new insights into AD epidemiology, biomarkers, endotypes, prevention, and comorbidities. Going forward, we expect future mechanistic insights and therapeutic advances to broaden physicians’ ability to diagnose and manage AD patients, and perhaps to find a cure for this chronic condition.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0091-6749
1097-6825
1097-6825
DOI:10.1016/j.jaci.2022.10.023